Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.42 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.42 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885814 | 0.92 | PRMT5 (0.46) | ENPP2PRMT5PORCNGRM2CHRM5 | |
| SCHEMBL1642524 | 0.82 | GRM5 (0.52) | — | |
| SCHEMBL31068250 | 0.80 | PDE2A (0.38) | PRMT5PER2GRM2 | |
| SCHEMBL29348964 | 0.80 | PDE2A (0.38) | PRMT5PER2GRM2 | |
| SCHEMBL6886663 | 0.79 | L3MBTL1 (0.55) | ENPP2PRMT5PORCNACHE | |
| SCHEMBL6884928 | 0.78 | ROCK2 (0.46) | ENPP2PRMT5 | |
| SCHEMBL6885751 | 0.77 | GRIN1 (0.47) | ENPP2PORCNGRM2ACHECHRM5 | |
| SCHEMBL1643046 | 0.74 | GRM5 (0.48) | — | |
| SCHEMBL6886805 | 0.74 | GRM2 (0.43) | ENPP2PRMT5PER2GRM2ACHE | |
| SCHEMBL13504002 | 0.74 | L3MBTL1 (0.54) | PER2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | ENPP2 1537/4885PRMT5 172/4885PORCN 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.